Cargando…
Single Stabilizing Point Mutation Enables High‐Resolution Co‐Crystal Structures of the Adenosine A(2A) Receptor with Preladenant Conjugates
The G protein‐coupled adenosine A(2A) receptor (A(2A)AR) is an important new (potential) drug target in immuno‐oncology, and for neurodegenerative diseases. Preladenant and its derivatives belong to the most potent A(2A)AR antagonists displaying exceptional selectivity. While crystal structures of t...
Autores principales: | Claff, Tobias, Klapschinski, Tim A., Tiruttani Subhramanyam, Udaya K., Vaaßen, Victoria J., Schlegel, Jonathan G., Vielmuth, Christin, Voß, Jan H., Labahn, Jörg, Müller, Christa E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310709/ https://www.ncbi.nlm.nih.gov/pubmed/35174942 http://dx.doi.org/10.1002/anie.202115545 |
Ejemplares similares
-
Irreversible Antagonists for the Adenosine A(2B) Receptor †
por: Temirak, Ahmed, et al.
Publicado: (2022) -
Structural basis for the regulatory interactions of proapoptotic Par-4
por: Tiruttani Subhramanyam, Udaya K, et al.
Publicado: (2017) -
Adrenergic Agonists Bind to Adrenergic-Receptor-Like Regions of the Mu Opioid Receptor, Enhancing Morphine and Methionine-Enkephalin Binding: A New Approach to “Biased Opioids”?
por: Root-Bernstein, Robert, et al.
Publicado: (2018) -
Mutual Enhancement of Opioid and Adrenergic Receptors by Combinations of Opioids and Adrenergic Ligands Is Reflected in Molecular Complementarity of Ligands: Drug Development Possibilities
por: Root-Bernstein, Robert, et al.
Publicado: (2019) -
Crystal structure of adenosine A(2A) receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction
por: Claff, Tobias, et al.
Publicado: (2023)